- RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.
This study is for young people aged 6 to 17 with a rare blood condition called hypereosinophilic syndrome (HES). It's testing a medicine called mepolizumab to see if it can reduce how often their symptoms flare up and to check if it's safe.
For: Hypereosinophilic syndrome (HES)Spain · Netherlands - CompletedNot Applicable
Study of the effect of non-adherence to standard asthma preventer treatment (inhaled steroids) on response to biologic treatment (mepolizumab) in people with severe asthma
This study looks at people with severe asthma treated with a specialised drug called mepolizumab. Researchers want to find out if skipping or missing daily steroid inhalers stops mepolizumab from working properly. By checking health records, the team hopes to learn how best to support patients with their daily treatments.
For: Severe eosinophilic asthmaUnited Kingdom · England - Active not recruitingPHASE3
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
This study compares two treatments, benralizumab and mepolizumab, for a rare condition called Eosinophilic Granulomatosis with Polyangiitis (EGPA). Researchers want to see which one works better and is safer for people whose EGPA keeps coming back or isn't well controlled, even with other medicines.
For: Eosinophilic Granulomatous VasculitisUnited States · Belgium · Canada - Active not recruitingPHASE4
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
This study looks at how a medicine called mepolizumab (NUCALA) helps adults with severe asthma achieve better control, sometimes called 'remission'. It's a real-world study, meaning it observes people already using this treatment in their everyday lives to see its effects.
For: AsthmaUnited States · Belgium · Canada - Active not recruitingPHASE3
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study is looking at two medicines, Depemokimab and Mepolizumab, for adults with a rare condition called EGPA. We want to see how well they work and if they are safe when patients are already having standard treatment.
For: Eosinophilic Granulomatosis With PolyangiitisUnited States · Argentina · Austria